New Insights from EMBRACE Phase 2a Study on Emapalumab in Treating Sepsis

On March 18, 2026, Sobi® announced significant findings from its Phase 2a EMBRACE study that evaluated Gamifant® (emapalumab) in patients suffering from interferon-gamma-driven sepsis (IDS). These findings were presented at the prestigious International Symposium on Intensive Care and Emergency Medicine (ISICEM) by Professor Evangelos J. Giamarellos-Bourboulis, the President of the Hellenic Institute for the Study of Sepsis (HISS). The study was part of a collaborative research effort between HISS and Sobi, aimed at exploring advancements in sepsis treatment.

Sepsis stands as a major global health challenge, leading to significant mortality rates due to exaggerated immune responses to infections, often culminating in organ failure. This complex condition varies greatly among patients, indicating that a singular treatment approach may be inadequate. The EMBRACE study specifically focused on a subset of sepsis patients characterized by elevated interferon-gamma levels—a significant biomarker in sepsis immunopathology.

Recent results revealed that 60% of patients receiving a high dose of emapalumab experienced improvements in organ function compared to 40% of those treated with standard care plus a placebo. Moreover, the study reported a reduction in the 28-day mortality rate—40% in the high-dose emapalumab group versus 52% in the placebo cohort. These outcomes suggest that emapalumab might offer a new targeted therapeutic strategy against sepsis.

Professor Giamarellos-Bourboulis stated, “These findings support the concept that sepsis is not a single disease but a syndrome with different biological drivers.” This reinforces the need for precision medicine approaches in treating sepsis, where tailored therapies can provide significant benefits to patients based on their specific immunological profiles.

Clinical Trial Design Highlights
The EMBRACE study (NCT06694701) was a double-blind, randomized controlled trial conducted at 24 sites across Greece, enrolling a total of 75 patients. The trial was divided into three groups: two sets received Gamifant (low and high doses), while one group was administered a placebo alongside standard-of-care treatments. The primary goal was to achieve a decrease in the Sequential Organ Failure Assessment (SOFA) score of ≥1.4 points from baseline by the end of the treatment (28 days). Secondary endpoints included monitoring 28-day mortality, safety assessments, pharmacokinetics, and variations in inflammatory biomarkers.

Patients’ safety and tolerability were prioritized throughout the trial, with Gamifant demonstrating a safety profile consistent with existing data. Most adverse events were related to infections, but no novel safety concerns emerged from the trial.

Expanding the Horizon of Sepsis Treatment
Emapalumab’s mechanism involves neutralizing interferon-gamma, thereby potentially alleviating hyper-inflammatory responses that contribute to the devastating outcomes of sepsis. Current treatment options for this condition remain limited, with the interferon-gamma-driven sepsis endotype showing a heightened risk of mortality. As noted by Lydia Abad-Franch, Chief Medical Officer at Sobi, “Sepsis represents a leading cause of mortality worldwide and treatment options remain limited.” The EMBRACE study's promising results have sparked discussions with regulatory authorities for the next steps in clinical development, aiming to establish an additional indication for emapalumab in this critical area.

The Future of Sepsis Research and Treatment
The significance of the EMBRACE study lies not only in its immediate findings but also in its contributions to a growing body of research advocating for differentiated treatment strategies based on sepsis endotypes. With further study and validation, emapalumab could reshape the landscape of sepsis therapies and ultimately improve patient outcomes. The Hellenic Institute for the Study of Sepsis continues to spearhead groundbreaking research in this field, underscoring the urgency and necessity for targeted therapies.

In summary, the EMBRACE Phase 2a study offers hope for better management of interferon-gamma-driven sepsis and highlights the importance of tailored approaches in treating a condition that has historically stymied medical advancements. As we look to the future, the outcomes of this study could pave the way for more effective clinical interventions and ultimately save lives.